Overview

Dementia Associated with Alzheimer’s Disease Market is estimated to value over USD 6.5 billion by 2027 end and register a CAGR of over 4.3% during the forecast period 2020 to 2027.

Factors which have been anticipated to boost the dementia associated with Alzheimer’s disease market growth includes growing geriatric population, a hike in the presence of Alzheimer’s disease on a scale, boost in the research and development expenditure and plenty of alternatives in treatment. In addition, an abundance of research and development endeavors in disease altering drugs and an augmentation in investment by major market players in clinical studies pertinent to enhanced treatment alternatives are instrumental in the expansion of the market size during the forecast time frame. Although, the exorbitant costs of the enhanced treatment facilities as well as the detrimental side-effects linked with specific treatments count as some of the reasons that may restrain the market growth.

Going by the segmentation of the drug class, the market is fragmented into memantine, combined drug (donepezil & memantine), cholinesterase/cholinergic, inhibitor and others. In the segment of cholinesterase/cholinergic inhibitor, it is to be observed this segment is controlling the market size of dementia associated with Alzheimer’s disease. This inhibitor, in value terms, is the first phase of treatment for AD and is a commonly prescribed drug for AD. This segment is predicted to experience considerable CAGR, in part, because of the positive attributes in the treatment of dementia ranging from mild to severe. At present, there is no known treatment that can alter the Alzheimer’s disease, and the treatments that does exist for AD relief are known as cholinesterase inhibitors.

The segment for memantine is estimated to grow at a considerable CAGR, due to the properties that it contains to treat AD that is moderate to severe.

With the distribution channel segment, it has been bifurcated into retail, hospital and online pharmacies. The hospital pharmacies are expected to capture significant market share during the forecast timeline owing to affordable medication. The online pharmacies is estimated to encounter high growth since there is an easy accessibility of drugs at the comfort of one’s home at a reduced rate.

Key players who dominate this market includes Ono Pharmaceutical Co., Eisai Co., Ltd., Johnson & Johnson Services, Inc., Novartis AG, Allergan plc., Merz Pharma GmbH & Co. KGaA., F. Hoffmann-La Roche Ltd, Daiichi Sankyo Company, Pfizer, Inc., Limited, Ltd, H. Lundbeck A/S.

Dementia Associated with Alzheimer’s Disease Market Segmentation:

By Drug Class

•  Cholinergic/ Cholinesterase (ChE) Inhibitors 
•  Donepezil
•  Galantamine
•  Rivastigmine
•  Memantine
•  Combined Drug (Memantine & Donepezil) and Others

By Distribution Channel

• Hospital Pharmacies
• Retail
• Online Sales

By Region

• Europe
• North America
• Asia Pacific
• Latin America
• Middle East & Africa

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the dementia associated with Alzheimer’s disease market by drug class, by distribution channel, and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions

Table of Contents

1 Introduction 

1.1 Objectives of the Study 

1.2 Market Definition 

        1.2.1 Markets Covered

        1.2.2 Years Considered for the Study

1.3 Currency 

1.4 Limitations 

1.5 Stakeholders 

2 Research Methodology 

2.1 Research Approach 

2.2 Research Data 

        2.2.1 Secondary Sources

                 2.2.1.1 Key Data From Secondary Sources

        2.2.2 Primary Sources

                 2.2.2.1 Key Data From Primary Sources

                 2.2.2.2 Breakdown of Primary Interviews

2.3 Market Size Estimation 

2.4 Market Breakdown and Data Triangulation 

2.5 Research Assumptions 

3 Executive Summary 

4. Market Overview

     4.1. Introduction

            4.1.1. Drug Class Definition

            4.1.2. Industry Evolution / Developments

     4.2. Overview

     4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

     4.4. Global Dementia Associated with Alzheimer's Disease Market Analysis and Forecast, 2020–2027

            4.4.1. Market Value (US$ Mn) Projections

     4.5. Porter’s Five Force Analysis

5. Market Outlook

     5.1. Disease Prevalence & Incidence Rate Globally with Key Countries

     5.2. Pipeline Analysis

6. Global Dementia Associated with Alzheimer's disease Market Analysis and Forecast, by Drug Class

     6.1. Introduction & Definition

     6.2. Key Findings / Developments

     6.3. Market Value Forecast, by Drug Class, 2020–2027

            6.3.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 

                     6.3.1.1. Donepezil 

                     6.3.1.2. Galantamine

                     6.3.1.3. Rivastigmine

            6.3.2. Memantine 

            6.3.3. Combined Drug (Memantine & Donepezil) and Others

     6.4. Market Attractiveness, by Drug Class

7. Global Dementia Associated with Alzheimer's disease Market Analysis and Forecast, by Distribution Channel 

     7.1. Introduction & Definition

     7.2. Key Findings / Developments

     7.3. Market Value Forecast, by Distribution Channel, 2020–2027

            7.3.1. Hospital Pharmacies

            7.3.2. Retail 

            7.3.3. Online Sales 

     7.4. Market Attractiveness, by Distribution Channel 

8. Global Dementia Associated with Alzheimer's Disease Market Analysis and Forecast, by Region

     8.1. Key Findings

     8.2. Market Value Forecast, by Region

            8.2.1. North America 

            8.2.2. Europe 

            8.2.3. Asia Pacific 

            8.2.4. Latin America 

            8.2.5. Middle East & Africa 

     8.3. Market Attractiveness, by Country/Region

9 Competition Landscape

     9.1. Market Player – Competition Matrix (By Tier and Size of companies)

     9.2. Market Share Analysis by Company (2020)

     9.3. Market Footprint Analysis

            9.3.1. By Region

            9.3.2. By Drug Class Type

     9.4. Competitive Business Strategies

     9.5. Company Profiles

            9.5.1. Merz Pharma GmbH & Co. KGaA 

                     9.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                     9.5.1.2. Product Portfolio

                     9.5.1.3. SWOT Analysis

                     9.5.1.4. Financial Overview

                     9.5.1.5. Strategic Overview

            9.5.2. Novartis AG  

                     9.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                     9.5.2.2. Product Portfolio

                     9.5.2.3. SWOT Analysis

                     9.5.2.4. Financial Overview

                     9.5.2.5. Strategic Overview

            9.5.3. Allergan plc.

                     9.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                     9.5.3.2. Product Portfolio

                     9.5.3.3. SWOT Analysis

                     9.5.3.4. Financial Overview

                     9.5.3.5. Strategic Overview

            9.5.4. Pfizer, Inc.  

                     9.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                     9.5.4.2. Product Portfolio

                     9.5.4.3. SWOT Analysis

                     9.5.4.4. Financial Overview

                     9.5.4.5. Strategic Overview

            9.5.5. Daiichi Sankyo Company, Limited  

                     9.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                     9.5.5.2. Product Portfolio

                     9.5.5.3. SWOT Analysis

                     9.5.5.4. Financial Overview

                     9.5.5.5. Strategic Overview

            9.5.6. Ono Pharmaceutical Co., Ltd. 

                     9.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                     9.5.6.2. Product Portfolio

                     9.5.6.3. SWOT Analysis

                     9.5.6.4. Financial Overview

                     9.5.6.5. Strategic Overview

            9.5.7. Johnson & Johnson Services, Inc. 

                     9.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                     9.5.7.2. Product Portfolio

                     9.5.7.3. SWOT Analysis

                     9.5.7.4. Financial Overview

                     9.5.7.5. Strategic Overview

            9.5.8. Eisai Co., Ltd. 

                     9.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                     9.5.8.2. Product Portfolio

                     9.5.8.3. SWOT Analysis

                     9.5.8.4. Financial Overview

                     9.5.8.5. Strategic Overview

            9.5.9. H. Lundbeck A/S 

                     9.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                     9.5.9.2. Product Portfolio

                     9.5.9.3. SWOT Analysis

                     9.5.9.4. Financial Overview

                     9.5.9.5. Strategic Overview

            9.5.10. F. Hoffmann-La Roche Ltd.  

                     9.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                     9.5.10.2. Product Portfolio

                     9.5.10.3. SWOT Analysis

                     9.5.10.4. Financial Overview

                     9.5.10.5. Strategic Overview 

10 Research Finding and Conclusion

11 Research Methodology

12 Research Data Source

Tables

Figures